↓ Skip to main content

Dove Medical Press

Article Metrics

Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib

Overview of attention for article published in Biologics: Targets & Therapy, February 2016
Altmetric Badge

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
36 Mendeley
Title
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
Published in
Biologics: Targets & Therapy, February 2016
DOI 10.2147/btt.s67844
Pubmed ID
Authors

Javier Pinilla-Ibarz, Josephine Emole, Taiwo Talabi

Abstract

Chronic myelogenous leukemia (CML) is a pluripotent stem cell disease characterized by the presence of the Philadelphia chromosome and the bcr-abl gene. The discovery of tyrosine kinase inhibitors (TKIs) revolutionized therapy for CML, such that durable response, increased overall survival, and increased progression-free survival of patients in chronic phase CML is now possible. Due to resistance and intolerance to imatinib, there was need for development of second- and third-generation TKIs for the treatment of CML. This review examines the role of nilotinib, an oral second-generation TKI, in the treatment of Philadelphia positive CML. The pharmacology, efficacy, and safety of nilotinib are critically evaluated. Patient-related issues, including tolerance, drug interactions, and quality of life issues are also examined.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Indonesia 1 3%
Unknown 35 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 22%
Student > Bachelor 6 17%
Student > Postgraduate 4 11%
Student > Ph. D. Student 2 6%
Professor 2 6%
Other 5 14%
Unknown 9 25%
Readers by discipline Count As %
Medicine and Dentistry 10 28%
Biochemistry, Genetics and Molecular Biology 5 14%
Pharmacology, Toxicology and Pharmaceutical Science 4 11%
Chemistry 2 6%
Agricultural and Biological Sciences 2 6%
Other 3 8%
Unknown 10 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 February 2016.
All research outputs
#5,267,398
of 7,313,486 outputs
Outputs from Biologics: Targets & Therapy
#69
of 136 outputs
Outputs of similar age
#182,334
of 282,523 outputs
Outputs of similar age from Biologics: Targets & Therapy
#6
of 8 outputs
Altmetric has tracked 7,313,486 research outputs across all sources so far. This one is in the 24th percentile – i.e., 24% of other outputs scored the same or lower than it.
So far Altmetric has tracked 136 research outputs from this source. They receive a mean Attention Score of 2.3. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 282,523 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.